Biotech Values

[DewDiligence]

Some analysts still see Effient exceeding $1 billion in annual sales eventually, but Wall Street enthusiasm for the drug has generally waned due to delayed regulatory approval and the bleeding risk associated with the drug.

The enthusiasm for Effient has also been subdued by the expectations for Brilinta. Shops that might have switched from Plavix to Effient may now prefer to stick with Plavix until Brilinta hits the market, thereby making one change instead of two.